Jpmorgan Chase & CO Compass Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 45,883 shares of CMPX stock, worth $78,001. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,883
Previous 38,353
19.63%
Holding current value
$78,001
Previous $75,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CMPX
# of Institutions
84Shares Held
92.7MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$38 Million0.54% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.1MShares$18.9 Million0.02% of portfolio
-
Blackstone Inc New York, NY7.69MShares$13.1 Million0.03% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$11.2 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD5.51MShares$9.37 Million0.17% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $172M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...